Patents Assigned to Glaxosmithkline Intellectual Property Development
  • Substituted pyridines as DNMT1 inhibitors
    Patent number: 12285436
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: April 29, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril, Megan Ketchum, Todd Koretke, Elizabeth Ann Moroz, Grace Price
  • Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer
    Publication number: 20250122297
    Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
    Type: Application
    Filed: December 18, 2024
    Publication date: April 17, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sanjay KHANDEKAR, Patrick MAYES, Joanna OPALINSKA
  • Processes for the production of oligonucleotides
    Patent number: 12275983
    Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 15, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andreas Crameri, Malcolm Leithhead Hill, David Graham Tew
  • TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS
    Publication number: 20250092053
    Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
    Type: Application
    Filed: December 3, 2024
    Publication date: March 20, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. CHARNLEY, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
  • Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases
    Publication number: 20250084112
    Abstract: Compounds of formula (1) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (1), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 13, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jie GUANG, David Glenn WASHBURN
  • Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors
    Patent number: 12247033
    Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
    Type: Grant
    Filed: February 26, 2024
    Date of Patent: March 11, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. Charnley, Janos Botyanszki, Xiaoyang Dong, Philip Gareth Humphreys, Bryan Wayne King, Kimberly Katherine Marcus, Joseph Pero, Alexander Joseph Reif, Daohua Zhang, Attiq Rahman, Kenneth Allen Newlander, Kenneth Wiggall, Joshi Ramanjulu
  • Treatment for primary amyloidosis with anti-BCMA binding protein
    Patent number: 12234293
    Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: February 25, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
  • Anti-BCMA antibody drug conjugate combination treatment for cancer
    Patent number: 12227585
    Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
    Type: Grant
    Filed: August 22, 2023
    Date of Patent: February 18, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
  • 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use
    Patent number: 12221444
    Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: February 11, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: John G. Catalano, Pek Yoke Chong, Hamilton D. Dickson, Martin R. Leivers, Jason Gordon Weatherhead
  • INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN FOR USE IN TREATING POLYANGIITIS, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), OR CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP)
    Publication number: 20250042985
    Abstract: The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.
    Type: Application
    Filed: December 1, 2022
    Publication date: February 6, 2025
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Daren J. AUSTIN, Alienor C. BERGES, Nicholas P. BIRD, Myrna A. MONCK, Isabelle J. POULIQUEN, Melissa A. SHUMAN, Chiara ZECCHIN
  • Methods for administering STING agonists
    Patent number: 12178851
    Abstract: The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 31, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: George Scott Pesiridis, Jean-Luc Tran, Jingsong Yang, Joshi M Ramanjulu
  • IL-7 Binding Proteins and Their Use in Medical Therapy
    Publication number: 20240425581
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Application
    Filed: September 3, 2024
    Publication date: December 26, 2024
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
  • Biopharmaceutical Compositions and Stable Isotope Labeling Peptide Mapping Method
    Publication number: 20240369568
    Abstract: Disclosed herein are stable isotope labeling (SIL) peptide mapping methods for accurate and sensitive conjugation site quantitation. Also disclosed herein are compositions comprising antibody drug conjugates (ADCs) that target BCMA.
    Type: Application
    Filed: August 2, 2022
    Publication date: November 7, 2024
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Tyler Keith DAVIS, Hillary Amber SCHUESSLER
  • IL-7 binding proteins and their use in medical therapy
    Patent number: 12122828
    Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: October 22, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Gerben Bouma, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
  • Compounds
    Patent number: 11999746
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: June 4, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • MrgX2 antagonists
    Patent number: 11976057
    Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: May 7, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III
  • Heterocyclic amides useful as protein modulators
    Patent number: 11970480
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: April 30, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
  • Hydroxypyridoxazepines as NRF2 activators
    Patent number: 11945826
    Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 2, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
  • Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
    Publication number: 20240083896
    Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 14, 2024
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiaoyang DONG, Mark Andrew ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, Joseph J. ROMANO, David Glenn WASHBURN
  • Display screen with graphical user interface
    Patent number: D1053891
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: December 10, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Kaushal Kishore, Mala Kiran Talekar